RxDoctor Payments Data

Rodrigo Pereira, MD

Family Medicine · Orlando, FLNPI 1477741817

Payments from drug & device makers

$786in general payments, 2019–2025

Across 43 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$198
  • GSK$191
  • AstraZeneca$125
  • Johnson & Johnson$67
  • Astellas Pharma US Inc$50
  • Sanofi-aventis U.S. LLC$33
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$786 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$9,020
Medicare patients
14
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$68,503
JardianceEmpagliflozin47$61,322
OzempicSemaglutide44$52,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,323
TrulicityDulaglutide14$16,555
MounjaroTirzepatide15$16,315
XareltoRivaroxaban16$15,261
SymbicortBudesonide/Formoterol Fumarate26$9,581
Albuterol Sulfate HfaAlbuterol Sulfate163$5,731
Pregabalin52$4,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,578
Rosuvastatin Calcium314$2,443
Gabapentin120$1,621
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$1,300
Levothyroxine Sodium121$1,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$198$52,50244 claims
GSKTrelegy Ellipta$191$27,32328 claims
Johnson & JohnsonXarelto$67$15,26116 claims
AstraZenecaSymbicort$125$9,58126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →